0.91
-0.0167(-1.79%)
Currency In USD
| Previous Close | 0.93 |
| Open | 0.94 |
| Day High | 0.99 |
| Day Low | 0.86 |
| 52-Week High | 18.9 |
| 52-Week Low | 0.82 |
| Volume | 400,275 |
| Average Volume | 126,371 |
| Market Cap | 3.81M |
| PE | 0.02 |
| EPS | 48.21 |
| Moving Average 50 Days | 1.14 |
| Moving Average 200 Days | 3.18 |
| Change | -0.02 |
If you invested $1000 in Oragenics, Inc. (OGEN) 10 years ago, it would be worth $1.44 as of December 14, 2025 at a share price of $0.914. Whereas If you bought $1000 worth of Oragenics, Inc. (OGEN) shares 5 years ago, it would be worth $35.43 as of December 14, 2025 at a share price of $0.914.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oragenics Q2 2025 Shareholder Update
GlobeNewswire Inc.
Aug 11, 2025 12:45 PM GMT
Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering biotechnology company striving
Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial
GlobeNewswire Inc.
Jul 31, 2025 12:30 PM GMT
Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion StudySARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasa
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
GlobeNewswire Inc.
Jul 16, 2025 12:39 PM GMT
SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Ste